# FDA requires GLP-1 labels to mention possible link to rare eye condition

- URL: https://talkfuse.com/story/fda-warns-of-rare-eye-condition-causing-blindness-from-glp-1-weight-loss-medications/
- Published: 2026-11-10T20:18:14+00:00
- Updated: 2026-11-10T20:35:19+00:00
- Original publisher: The Guardian (publisher lean: Left)
- Original article: https://www.theguardian.com/us-news/2026/nov/10/fda-glp-1-weight-loss-blindness-risk
- Topics: Americas, Culture, Food, Health, Medicine, World

## Key points

- FDA orders NAION warnings on all GLP-1 labels.
- Trials found 10 probable cases among GLP-1 users.
- The evidence suggests a possible risk, not proven causation.

## Summary

The US Food and Drug Administration will require all GLP-1 medicines to carry a warning about a possible link to NAION, a rare condition that can cause sudden, painless and sometimes permanent vision loss. The decision follows an assessment of evidence suggesting a potential increased risk; it does not establish that the medicines cause the condition.

The FDA reviewed 126 clinical trials involving more than 134,200 people and identified 15 probable NAION cases: 10 among GLP-1 users and five among people receiving a placebo, with none among patients taking other glucose-lowering medicines. It estimated 6.4 cases per 100,000 person-years among GLP-1 users, compared with 3.8 in the comparison groups. NAION risk factors include diabetes, smoking and high blood pressure, and there is currently no treatment to reverse its vision loss. Novo Nordisk said the data do not prove cause and effect and that it remains confident in the medicines’ benefit-risk profile.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.